Abstract
Preliminary studies using anti-KIT antibodies (Huang et al. 2008), anti-TNF-α antibodies (Gounaris et al. 2007) or the MC stabilizer disodium cromoglycate (cromolyn) (Soucek et al. 2007) in mouse models demonstrated promising results even if administered after the initiation of tumour development. Treatment of mice bearing mammary adenocarinoma and pancreatic cancer with cromolyn led to clotting of blood vessels, hypoxia and tumour cell apoptosis (Samoszuk and Corwin 2003a, b; Soucek et al. 2007). Unfortunately, cromolyn is a weak inhibitor of human MC secretion and is poorly adsorbed, so it is unlikely to be effective in treating cancer in humans.
Keywords
Imatinib Mesylate Tumour Cell Apoptosis Medicinal Leech Disodium Cromoglycate Bone Marrow Angiogenesis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Copyright information
© Springer Science+Business Media B.V. 2011